Stocktoria
Cellectar Biosciences, Inc. CLRB
Cellectar Biosciences, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $11.5M | $26.1M | $27.3M | $19.2M | $17.6M | $10.1M | $9.0M | $6.8M | $9.5M | $4.8M |
| Operating income | -$23.0M | -$51.8M | -$39.0M | -$28.8M | -$24.1M | -$15.3M | -$14.2M | -$13.3M | -$13.6M | -$9.4M |
| Income tax | — | $66,000 | -$60,000 | -$60,000 | — | — | $0 | $0 | $0 | $0 |
| Net income | -$21.8M | -$44.6M | -$42.8M | -$28.6M | -$24.1M | -$15.1M | -$14.1M | -$13.2M | -$13.6M | -$6.2M |
| EPS (diluted) | $-8.35 | $-41.89 | $-3.50 | $-4.05 | $-4.35 | $-1.84 | — | — | — | — |
| Operating cash flow | -$23.1M | -$47.6M | -$32.4M | -$25.2M | -$22.6M | -$13.9M | -$11.7M | -$11.4M | -$11.0M | -$8.3M |
| Free cash flow | -$23.1M | -$47.7M | -$33.2M | -$25.4M | -$22.7M | -$14.0M | -$11.7M | -$11.8M | -$11.4M | -$8.4M |
| Cash & equivalents | $13.2M | $23.3M | $9.6M | $19.9M | $35.7M | $57.2M | $10.6M | $13.3M | $10.0M | $11.4M |
| Total assets | $15.0M | $25.5M | $12.1M | $21.6M | $37.2M | $58.7M | $12.3M | $15.1M | $12.9M | $15.3M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $6.1M | $4.2M | $3.9M | $3.2M | $1.8M | $2.1M | $1.8M |
| Shareholders' equity | $8.5M | $14.3M | -$15.2M | $8.2M | $33.0M | $54.8M | $9.1M | $13.3M | $10.8M | $13.5M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.